Clinical Trials Logo

Adenomyosis clinical trials

View clinical trials related to Adenomyosis.

Filter by:

NCT ID: NCT06373822 Recruiting - Adenomyosis Clinical Trials

New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs

ADENO-MIRNA
Start date: March 21, 2024
Phase:
Study type: Observational

Objectives: To identify differentially expressed miRNAs in the blood of adenomyosis patients in view to develop new diagnostic methods Hypotheses Circulating miRNAs may be abnormally expressed in patients suffering from adenomyosis and could be used to diagnose the disease Study Design Blood samples will be collected from healthy subjects and adenomyosis patients and miRNAs will be isolated and analyzed to detect potential differences.

NCT ID: NCT06364592 Not yet recruiting - Dysmenorrhea Clinical Trials

Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis

Start date: April 2024
Phase: N/A
Study type: Interventional

The aim of this study is to preliminarily evaluate the is to assess the effects and safety of electroacupuncture for moderate to severe dysmenorrhea secondary to adenomyosis.

NCT ID: NCT06250569 Not yet recruiting - Adenomyosis Clinical Trials

Adenomyosis in Fertile Women in MUSA Criteria

Start date: February 2024
Phase:
Study type: Observational

1. To estimate the prevalence of adenomyosis in fertile women aged 18-30 years using the revised MUSA ultrasound criteria. 2. To evaluate clinical risk factors that are associated with adenomyosis diagnosis in this population

NCT ID: NCT06239376 Recruiting - IVF Clinical Trials

Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients

FET-ADE
Start date: February 19, 2024
Phase: N/A
Study type: Interventional

This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF/ICSI. Specifically, it seeks to address the following key questions: 1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI - AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer? 2. What are the common side effects of the GnRHa+AI - AC regimen? Eligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of two groups: GnRHa+AI - AC or AC. In the GnRHa+AI - AC group, participants will be pre-treated with GnRH agonist and letrozole two months before endometrial preparation. After this period, participants will return for endometrial preparation, and any side effects resulting from the down regulation will be evaluated. In contrast, the AC group will receive standard treatment.

NCT ID: NCT06223464 Active, not recruiting - Adenomyosis Clinical Trials

Evaluation of the Relationship Between Adenomyosis and Elastographic Properties of the Cervix

Start date: October 18, 2023
Phase:
Study type: Observational

This study aims to evaluate the potential of cervical elastography, a non-invasive method, in the accurate diagnosis and clinical course of adenomyosis. Cervical elastography is an imaging method that measures the elasticity properties of cervical tissue using ultrasound technology. This method may be helpful in providing information about the development and clinical course of adenomyosis.

NCT ID: NCT06211569 Recruiting - Clinical trials for Elective Fertility Preservation

Study of the Prevalence of Endometriosis and Adenomyosis

PrevADEOSE
Start date: April 4, 2024
Phase:
Study type: Observational

Our study aims to assess the prevalence of adenomyosis and endometriosis in patients consulting for elective fertility preservation through the diagnosis of these pathologies by transvaginal pelvic ultrasound. Imaging data will be compared with clinical data (patient characteristics, clinical symptoms) as well as the assessment of anxiety, depression, and quality of life collected from the women.

NCT ID: NCT06174792 Not yet recruiting - Adenomyosis Clinical Trials

Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis

Start date: December 30, 2023
Phase:
Study type: Observational

Adenomyosis is a common benign condition of fertile women and is characterized by dysmenorrhea, hypermenorrhea, abnormal uterine bleeding, infertility and chronic pelvic pain. To date, no clear guidelines are available regarding the treatment of adenomyosis, however, resembling endometriosis, as it too is a sex hormone-dependent inflammatory condition, numerous hormonal and non-hormonal treatments are currently being used off-label in the treatment of this condition, succeeding in controlling, sometimes not fully efficiently, the resulting symptoms. Among hormonal treatments, progestins have been proposed. Decreased expression of progesterone receptors (PR) A and B has been observed in adenomyotic tissue, similar to endometriosis. Progesterone induces antiproliferative activity through binding to its receptors. The observed reduction in PR expression could partially explain the pathogenesis of adenomyosis and the poor response to progestins. Although adenomyotic tissue has lower levels of PR, a good response to high-dose topical progesterone has been demonstrated. Although several molecules have been tested, such as levonorgestrel, dienogest, and danazol, to date there are no randomized controlled trials on the use of progestins in the treatment of adenomyosis that would allow clear guidelines on their use in this setting. Among the progestins commercially available today is drospirenone, which is used clinically as a progestin in oral contraceptives. Drospirenone is a synthetic progestin similar to human progesterone and is a potent inhibitor of mineralocorticoid activity. Drospirenone has been shown to significantly reduce the diameter and maximal volume of ovarian endometrioma, reduce dysmenorrhea, reduce postoperative anatomic and symptomatic recurrence rates, and decrease serum CA125 levels. Drospirenone also acts on the endometrium, reducing its proliferation and thus improving menorrhagia symptoms and has also been shown to reduce Ki-67 expression in the human endometrium when administered orally with and without E2. Despite reports of these clinical effects on endometriosis, the direct effects of drospirenone on adenomyosis have never been tested. The aim of study is to evaluate the efficacy and safety of drospirenone in the treatment of adenomyosis, and its impact on improved quality of life and sexual life.

NCT ID: NCT06123975 Recruiting - Adenomyosis Clinical Trials

Adenomyosis Patients With Infertility and Immunological Factors

Start date: March 1, 2024
Phase:
Study type: Observational

Infertile patients with adenomyosis who met the inclusion and exclusion criteria, after signing the informed consent form, the researchers recorded the clinical information of the patients and initiated the in vitro fertilization-embryo transfer (IVF-ET) procedure. Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation. By analyzing the changes of immune cells and molecules in the peripheral blood of the patients, role of immune factors in infertility combined with adenomyosis was further explored.

NCT ID: NCT06117410 Recruiting - Ultrasound Clinical Trials

Assessing Ultrasonographic Severity of Adenomyosis

AdenoStaging
Start date: February 8, 2021
Phase:
Study type: Observational

The aim of this pilot study is to develop a feasible and quantifiable ultrasonographic method to grade the severity of adenomyosis and to determine the interobserver variation.

NCT ID: NCT06043583 Recruiting - Adenomyosis Clinical Trials

Intrauterine Device Versus Uterine Artery Embolization for Adenomyosis

Start date: July 21, 2023
Phase: N/A
Study type: Interventional

The primary purpose of this study is to compare the therapeutic efficacy of intrauterine device and uterine artery embolization for uterine adenomyosis.